Theralase Technologies Inc.

Theralase Technologies Inc.

March 31, 2009 09:30 ET

Theralase Advances on the Quest for Cancer Cure

TORONTO, ONTARIO--(Marketwire - March 31, 2009) - Theralase Technologies Inc. (TSX VENTURE:TLT) announces significant advances in pre-clinical research & development of light-activated photodynamic compounds (PDC's) for the destruction of cancer cells.

Theralase Technologies, developer of the Theralase Super-Pulsed Laser has made major advances combining their patented bio-feedback laser technology with light-activated photodynamic compounds (PDC's) - in conjunction with University Health Network (Ontario Cancer Institute and Princess Margaret Hospital) and Virginia Tech- to selectively target and destroy cancer cells.

Research in pre-clinical trials has indicated that individually neither the compounds nor the laser has any effect on normal or cancerous cells - attesting to the inherent safety of each. However, once the compounds and Theralase technology are combined, the result was complete eradication of cancer cells - in the absence of oxygen, a unique and highly prized characteristic in the destruction of cancer cells.

Lothar Lilge, PH.D (Ontario Cancer Institute), lead researcher stated, "I am extremely excited about the possibilities and opportunities that these compounds present in the destruction of cancer cells. The ability to completely destroy cancer cells without oxygen is a unique opportunity for treating solid core tumors such as breast, prostate, lung and brain."

Roger Dumoulin-White, President and CEO of Theralase Technologies Inc. remarks, "We are delighted to work with Dr. Lilge and his team at the renowned Ontario Cancer Institute at Princess Margaret Hospital, in the research and development of our patented PDC's for the destruction of cancer cells. The initial results are extremely encouraging as we scientifically confirm that the combination of the Theralase TLC-3000 Light Source and our patented light-activated PDC's can completely and selectively destroy cancer cells."

Current investigation will determine the best combination of light-activated compound and cancer cell line for evaluation in a small animal cancer model slated for 2009 and, pending successful outcomes, solidify the opportunity for further clinical trials in humans as early as 2010.

Dumoulin-White affirms, "It was always a key strategic initiative of the company to pursue the elusive cure for cancer and now it looks like we may be well on our way to achieving this lofty goal with our Theralase PDC technology."

Theralase Technologies Inc. is focused on a two-part strategy:

1. Production, marketing & distribution of the Theralase Super-Pulsed Laser for sale to health care practitioners and focused on the treatment of chronic pain, sports injuries & wounds.

2. Commercialization of cancer treatment through progressive research, clinical trials and advancement of new and exciting work in the direct destruction of cancers.

This press release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the contents of this release.

Contact Information